Skip to main navigation Skip to search Skip to main content

Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases

  • Burkhard Weisser
  • , Sven Wassmann
  • , Hans-Georg Predel
  • , Roland E Schmieder
  • , Anton Gillessen
  • , Thomas Wilke
  • , Jörg Blettenberg
  • , Olaf Randerath
  • , Antje Mevius
  • , Michael Böhm

Publication: Contribution to journal › Journal articles › Research › peer-review

Abstract

AIMS: Our study aimed to assess whether a single pill concept (SPC) is superior to a multi-pill concept (MPC) in reducing cardiovascular (CV) events, all-cause death, and costs in CV patients.

METHOD AND RESULTS: Anonymized medical claims data covering 2012-2018, including patients with hypertension, dyslipidaemia, and CV diseases who started a drug therapy either as SPC or identical MPC were analysed after 1:1-propensity score matching. Hospitalizations with predefined CV events, all-cause mortality, and costs were studied in 25 311 patients with SPC and 25 311 patients with MPC using incidence rate ratios (IRRs) and non-parametric tests for continuous variables.IRRs were significantly lower for SPC: stroke (IRR = 0.77; 95% CI 0.67-0.88; P < 0.001), transitory ischaemic attack (IRR = 0.61; 95% CI 0.48-0.78; P < 0.001), myocardial infarction (IRR = 0.76; 95% CI 0.63-0.90; P = 0.0016), coronary artery disease (IRR = 0.66; 95% CI 0.57-0.77; P < 0.001), heart failure (IRR = 0.59; 95% CI 0.54-0.64; P < 0.001), acute renal failure (IRR = 0.54; 95% CI 0.56-0.64; P < 0.001), all cause hospitalization (IRR = 0.72; 95% CI 0.71-0.74; P < 0.001), CV hospitalization (IRR = 0.63; 95% CI 0.57-0.69; P < 0.001), and all-cause mortality (IRR = 0.62; 95% CI 0.57-0.68; P < 0.001). Mean time to first events and time to death were also in favour of SPC. Mean total costs were 4708€ for SPC vs. 5.669€ for MPC, respectively (mean ratio 0.830, P < 0.001).

CONCLUSION: SPC is associated with lower incidence rates of CV events, time to CV events, and all-cause death, and is superior regarding pharmacoeconomic parameters and should therefore become standard of care to improve outcomes and reduce healthcare costs.

Original languageEnglish
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Volume10
Issue number8
Pages (from-to)686-693
Number of pages8
DOIs
Publication statusPublished - 11.01.2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research areas and keywords

  • Humans
  • Female
  • Cardiovascular Diseases/economics
  • Male
  • Aged
  • Middle Aged
  • Drug Costs
  • Time Factors
  • Treatment Outcome
  • Cardiovascular Agents/economics
  • Retrospective Studies
  • Cost-Benefit Analysis
  • Cost Savings
  • Economics, Pharmaceutical
  • Databases, Factual
  • Cause of Death
  • Incidence
  • Hospitalization

Fingerprint

Dive into the research topics of 'Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases'. Together they form a unique fingerprint.

Citation